Literature DB >> 18365867

Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.

S Kalla Singh1, D Moretta, F Almaguel, N R Wall, M De León, D De León.   

Abstract

Insulin-like growth factor II (IGF-II) plays a pivotal role in fetal and cancer development by signaling through the IGF-I and insulin receptors and activating the estrogen signaling cascade. We previously showed that precursor IGF-II (proIGF-II, the predominant form expressed in cancer) and not mature IGF-II (mIGF-II) blocks resveratrol (RSV) (a phytoalexin/anticancer agent)-induced cell death in MCF-7 cells. We hypothesize that proIGF-II regulates antiapoptotic proteins and/or the mitochondria to inhibit RSV actions and promote cell survival. This study examines the effect of mIGF-II and proIGF-II on survivin expression and mitochondrial polarization in response to RSV. RSV inhibits survivin expression and stimulates mitochondrial depolarization, caspase 7 activation and cell death. These effects were completely blocked by the addition of proIGF-II. RSV treatment had no effect on transfected MCF-7 cells constitutively expressing proIGF-II, while IGF-II siRNA transfection decreased survivin levels. Our results provide new insights for the potential use of proIGF-II as target for new anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18365867      PMCID: PMC3070206          DOI: 10.1080/08977190801886905

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  34 in total

Review 1.  Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm.

Authors:  Dario C Altieri
Journal:  J Cell Biochem       Date:  2004-07-01       Impact factor: 4.429

Review 2.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

3.  The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain.

Authors:  C Q Yang; X Zhan; X Hu; A Kondepudi; J F Perdue
Journal:  Endocrinology       Date:  1996-07       Impact factor: 4.736

4.  Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.

Authors:  M Jang; L Cai; G O Udeani; K V Slowing; C F Thomas; C W Beecher; H H Fong; N R Farnsworth; A D Kinghorn; R G Mehta; R C Moon; J M Pezzuto
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

5.  Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer.

Authors:  B Vischioni; P van der Valk; S W Span; F A E Kruyt; J A Rodriguez; G Giaccone
Journal:  Ann Oncol       Date:  2004-11       Impact factor: 32.976

6.  Overexpression of mature insulin-like growth factor (IGF)-II leads to growth arrest in Caco-2 human colon cancer cells.

Authors:  Eun Ji Kim; P Elly Holthuizen; Jaebong Kim; Jung Han Yoon Park
Journal:  Growth Horm IGF Res       Date:  2005-01-21       Impact factor: 2.372

7.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

Authors:  Takehiko Dohi; Elena Beltrami; Nathan R Wall; Janet Plescia; Dario C Altieri
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Sequence of a cDNA clone encoding human preproinsulin-like growth factor II.

Authors:  G I Bell; J P Merryweather; R Sanchez-Pescador; M M Stempien; L Priestley; J Scott; L B Rall
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

9.  Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors.

Authors:  J F Perdue; T R LeBon; J Kato; B Hampton; Y Fujita-Yamaguchi
Journal:  Endocrinology       Date:  1991-12       Impact factor: 4.736

10.  Purification and characterization of a unique high molecular weight form of insulin-like growth factor II.

Authors:  L K Gowan; B Hampton; D J Hill; R J Schlueter; J F Perdue
Journal:  Endocrinology       Date:  1987-08       Impact factor: 4.736

View more
  16 in total

Review 1.  Resveratrol: challenges in translation to the clinic--a critical discussion.

Authors:  Lalita Subramanian; Sherry Youssef; Saswati Bhattacharya; Jason Kenealey; Arthur S Polans; Paul R van Ginkel
Journal:  Clin Cancer Res       Date:  2010-11-02       Impact factor: 12.531

Review 2.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

3.  Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes.

Authors:  S Kalla Singh; C Brito; Q W Tan; M De León; D De León
Journal:  Growth Factors       Date:  2011-09-13       Impact factor: 2.511

4.  Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.

Authors:  A E Richardson; N Hamilton; W Davis; C Brito; D De León
Journal:  Growth Factors       Date:  2011-03-16       Impact factor: 2.511

5.  Activation and reversal of lipotoxicity in PC12 and rat cortical cells following exposure to palmitic acid.

Authors:  Frankis G Almaguel; Jo-Wen Liu; Fabio J Pacheco; Carlos A Casiano; Marino De Leon
Journal:  J Neurosci Res       Date:  2009-04       Impact factor: 4.164

6.  Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; C Garberoglio; D De León
Journal:  Growth Horm IGF Res       Date:  2010-01-25       Impact factor: 2.372

7.  Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5.

Authors:  Tali Eilon; Itamar Barash
Journal:  BMC Genomics       Date:  2009-05-18       Impact factor: 3.969

8.  Precursor IGF-II (proIGF-II) and mature IGF-II (mIGF-II) induce Bcl-2 And Bcl-X L expression through different signaling pathways in breast cancer cells.

Authors:  S Kalla Singh; D Moretta; F Almaguel; M De León; Daisy D De León
Journal:  Growth Factors       Date:  2008-04       Impact factor: 2.511

9.  Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells.

Authors:  Agnieszka Gornowicz; Zbigniew Kałuża; Anna Bielawska; Halina Gabryel-Porowska; Robert Czarnomysy; Krzysztof Bielawski
Journal:  Mol Cell Biochem       Date:  2014-03-18       Impact factor: 3.396

10.  Expression of Intratumoral IGF-II Is Regulated by the Gene Imprinting Status in Triple Negative Breast Cancer from Vietnamese Patients.

Authors:  Vinodh Kumar Radhakrishnan; Lorraine Christine Hernandez; Kendra Anderson; Qianwei Tan; Marino De León; Daisy D De León
Journal:  Int J Endocrinol       Date:  2015-09-10       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.